Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Certificates of Supplementary Protection (CSP) and Applications - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 211428
Later capture
Certificates of Supplementary Protection (CSP) and Applications - Canada.ca
Jan 1, 2026
hc-20260101
ID 404921
updated4 sections changed
4 sections changed0 added0 removed+113 / -11 linesChange ratio: 5%
--- +++ @@ -3,7 +3,8 @@ The fee as of April 1, 2025 is $10,564 Register of Certificates of Supplementary Protection and Applications Notice: Publication of update to the Guidance Document: Certificate of Supplementary Protection Regulations-CSP Application Form (effective November 16, 2023)+CSP Application Form (effective October 28, 2025)+CSP Application Form (effective November 16, 2023 to October 27, 2025) CSP Application Form (effective January 6, 2021 to November 15, 2023) CSP Application Form (effective April 1, 2020 to January 5, 2021) CSP Application Form (effective May 15, 2019 to March 31, 2020)@@ -13,11 +14,7 @@ Background Register of Certificates of Supplementary Protection and Applications Register of Certificates of Supplementary Protection and Applications-(-PDF-, 151-KB-)+(PDF, 153 KB) Certificates of Supplementary Protection and Applications - Human Use Certificate of Supplementary Protection (CSP) and/or Application Number Medicinal Ingredient(s)@@ -76,6 +73,8 @@ 2713981 2029-02-06 Withdrawn+-+- 900035 antihemophilic factor (recombinant, B-domain deleted, pegylated) (also known as damoctocog alfa pegol) 210935@@ -178,6 +177,8 @@ 2416757 2021-07-20 Refused+-+- 900020 brigatinib 210369@@ -240,6 +241,8 @@ 2346257 2019-10-11 Refused+-+- 900118 ciltacabtagene autoleucel 262122@@ -254,12 +257,16 @@ 2462930 2022-10-09 Refused+-+- 900052 coagulation factor IX (recombinant), pegylated 201114 2665480 2027-10-04 Refused+-+- 900115 concizumab 267120@@ -274,6 +281,8 @@ 2837274 2032-05-25 Refused+-+- 900019 crisaborole 206906@@ -282,6 +291,14 @@ Issued 2026-02-17 2028-02-16+900149+crovalimab+285444+3005592+2036-12-16+Issued+2036-12-17+2038-12-16 900041 dacomitinib 214572@@ -352,6 +369,8 @@ 2606282 2026-04-28 Refused+-+- 900034 doravirine 211293@@ -400,6 +419,14 @@ Issued 2028-07-09 2030-07-08+900148+eplontersen sodium+274598+2921167+2034-05-01+Issued+2034-05-02+2036-05-01 900074 eptinezumab 233288@@ -488,6 +515,14 @@ Issued 2031-06-08 2033-06-07+900150+garadacimab+280174+2841185+2032-07-20+Pending+-+- 900055 gilteritinib fumarate 227918@@ -518,6 +553,8 @@ 2807847 2031-10-12 Refused+-+- 900133 glofitamab 265517@@ -532,6 +569,8 @@ 2763936 2030-05-28 Refused+-+- 900003 guselkumab 200590@@ -545,7 +584,9 @@ 288071 2982708 2036-07-01-Pending+Issued+2036-07-02+2038-07-01 900085 inclisiran sodium 243470@@ -560,6 +601,8 @@ 2781431 2030-12-06 Refused+-+- 900032 inotersen (inotersen sodium) 214274@@ -581,7 +624,9 @@ 283206 2917839 2034-07-14-Pending+Issued+2034-07-15+2036-07-14 900029 lanadelumab 213920@@ -598,6 +643,22 @@ Issued 2029-10-22 2031-10-21+900144+lazertinib mesylate+285014+2962914+2035-10-13+Issued+2035-10-14+2037-10-13+900146+lebrikizumab+272660+3031589+2037-09-22+Issued+2037-09-23+2039-06-25 900066 lefamulin (supplied as lefamulin acetate) 233292@@ -702,6 +763,14 @@ Issued 2022-10-12 2024-10-11+900143+nirsevimab+269388+2933200+2035-01-14+Issued+2035-01-15+2037-01-14 900122 nivolumab / relatlimab 256629@@ -732,6 +801,8 @@ 2780772 2030-11-15 Withdrawn+-+- 900091 palovarotene 252065@@ -754,6 +825,8 @@ 2997744 2033-09-12 Withdrawn+-+- 900140 perfluorohexyloctane 272066@@ -768,12 +841,16 @@ 2788253 2032-08-29 Refused+-+- 900098 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F)* *conjugated to diphtheria CRM197 protein 253111 2881420 2033-08-12 Withdrawn+-+- 900092 pneumococcal polysaccharide serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F)* *conjugated to CRM197 protein 247042@@ -812,6 +889,8 @@ 2696127 2028-08-08 Withdrawn+-+- 900068 remdesivir 240551@@ -820,6 +899,14 @@ Issued 2031-07-23 2033-07-22+900145+repotrectinib+284373+2936079+2035-01-23+Issued+2035-01-24+2037-01-23 900016 ribociclib (ribociclib succinate) 203884@@ -866,6 +953,8 @@ 2451258 2022-06-07 Refused+-+- 900046 romosozumab 197713@@ -874,6 +963,14 @@ Issued 2026-04-29 2028-04-28+900147+rozanolixizumab+274979+2872326+2033-05-13+Issued+2033-05-14+2035-05-13 900125 RSV subgroup A stabilized prefusion F protein / RSV subgroup B stabilized prefusion F protein 272785@@ -904,6 +1001,8 @@ 2747437 2029-12-16 Withdrawn+-+- 900059 siponimod 223225@@ -942,6 +1041,8 @@ 2670892 2027-11-30 Refused+-+- 900107 tafasitamab 247025@@ -1044,6 +1145,8 @@ 2600905 2026-03-01 Refused+-+- 900116 vericiguat 240862@@ -1147,7 +1250,6 @@ . For comments or questions, or to obtain a copy of a CSP or CSP application details, please contact the Office of Patented Medicines and Liaison by email at opml-bmbl@hc-sc.gc.ca-or by telephone at 613-941-7281.+. Page details-Date modified:-2025-04-08+2025-11-25